V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220006397 | 220002471 | 0 | 0 | Disease modification (D) | 2015-12-11 | 2015-12-11 | Nilotinib | N | N | 220030218 | NILOTINIB |
| 220006398 | 220002471 | null | null | Disease modification (D) | 2016-08-12 | 2016-08-12 | Nilotinib | N | N | 220030218 | NILOTINIB |
| 220006399 | 220002472 | 0 | 65 | Curative (C) | 2017-08-04 | 2017-08-11 | Nilotinib | N | N | 220030228 | NILOTINIB |
| 220006400 | 220002472 | 1.96 | 65.8 | Curative (C) | null | 2016-11-18 | AML 19 TRIAL | N | N | 220030228 | AML19 TRIAL |
| 220006401 | 220002472 | 1.7 | 0 | Curative (C) | 2017-01-17 | 2017-01-18 | Nilotinib | N | N | 220030228 | NILOTINIB |
| 220006402 | 220002472 | null | null | Curative (C) | 2016-05-04 | 2016-05-05 | AML MyeChild 01 A Mitozantrone/Cytarabine | 1 | N | 220030228 | NOT MATCHED |
| 220006403 | 220002473 | null | null | Disease modification (D) | 2016-02-06 | 2016-02-17 | Nilotinib | N | N | 220030238 | NILOTINIB |
| 220006404 | 220002473 | 1.55 | 63 | null | 2016-03-04 | 2016-03-04 | FLAG + Idarubicin | null | null | 220030238 | FLAG + IDARUBICIN |
| 220006405 | 220002474 | null | 52.1 | Curative (C) | 2015-02-02 | 2015-02-02 | APML Consolidation II ATRA,Idarubicin | N | N | 220030242 | NOT MATCHED |
| 220006406 | 220002474 | 1.6 | null | Curative (C) | 2017-03-25 | 2017-03-27 | FBC Conditionining | N | N | 220030242 | NOT MATCHED |
| 220006407 | 220002474 | null | null | Not known (9) | 2013-03-19 | 2013-03-19 | AML Interim Guidelines | N | N | 220030242 | NOT MATCHED |
| 220006408 | 220002474 | null | null | Disease modification (D) | 2015-03-21 | 2015-08-27 | Nilotinib | N | N | 220030242 | NILOTINIB |
| 220006409 | 220002474 | 1.58 | 86.1 | Curative (C) | null | 2013-01-25 | AML 19 TRIAL | Y | N | 220030242 | AML19 TRIAL |
| 220006410 | 220002475 | 0 | null | Not known (9) | 2014-11-19 | 2014-11-19 | Nilotinib | 2 | N | 220030250 | NILOTINIB |
| 220006411 | 220002475 | 1.62 | 73 | Curative (C) | 2016-07-12 | 2016-07-15 | FLAG + Idarubicin | null | N | 220030250 | FLAG + IDARUBICIN |
| 220006412 | 220002475 | 1.79 | 66.25 | Curative (C) | 2014-04-14 | 2014-04-15 | AML 19 TRIAL | Y | N | 220030250 | AML19 TRIAL |
| 220006413 | 220002475 | null | 38.1 | Disease modification (D) | 2016-07-12 | 2016-07-12 | AML Interim Guidelines | 2 | N | 220030250 | NOT MATCHED |
| 220006414 | 220002475 | null | 48 | Curative (C) | 2013-07-31 | 2014-01-13 | NB HRNBL-1 COJEC Ind COURSE A | Y | N | 220030250 | NOT MATCHED |
| 220006415 | 220002475 | 1.7 | 85 | Curative (C) | 2013-04-24 | 2013-04-24 | FLAG + Idarubicin | null | N | 220030250 | FLAG + IDARUBICIN |
| 220006416 | 220002475 | 1.7 | null | Curative (C) | 2017-01-21 | 2017-05-01 | null | N | N | 220030250 | NOT MATCHED |
| 220006417 | 220022003 | 0 | 0 | Curative (C) | 2017-11-20 | 2017-11-21 | Nilotinib | N | N | 220030271 | NILOTINIB |
| 220006418 | 220002476 | 0 | 89.7 | Disease modification (D) | 2013-07-31 | 2013-07-31 | Nilotinib | N | N | 220030272 | NILOTINIB |
| 220006419 | 220002476 | 1.61 | 100 | Curative (C) | 2014-05-18 | 2014-05-18 | AML 19 TRIAL | 1 | N | 220030272 | AML19 TRIAL |
| 220006420 | 220002476 | 1.8 | 54.6 | Curative (C) | 2016-04-18 | 2016-04-19 | AML 19 TRIAL | Y | N | 220030272 | AML19 TRIAL |
| 220006421 | 220002477 | null | 53.5 | Palliative (P) | 2017-10-13 | 2017-11-13 | Nilotinib | N | N | 220030276 | NILOTINIB |
| 220006422 | 220011412 | null | 55.3 | Disease modification (D) | 2014-01-07 | 2014-01-07 | Nilotinib | N | N | 220030281 | NILOTINIB |
| 220006423 | 220002478 | 1.76 | 86.7 | Curative (C) | 2013-03-26 | 2013-03-26 | FLAG + Idarubicin | 99 | N | 220030283 | FLAG + IDARUBICIN |
| 220006424 | 220011413 | 1.68 | 81.7 | Curative (C) | 2015-07-09 | 2015-07-09 | AML 19 TRIAL | N | N | 220030284 | AML19 TRIAL |
| 220006425 | 220011413 | 0 | 53.5 | null | 2016-02-09 | 2016-02-15 | Nilotinib | N | N | 220030284 | NILOTINIB |
| 220006426 | 220011413 | null | 0 | Curative (C) | 2013-06-18 | 2013-06-27 | null | 2 | N | 220030284 | NOT MATCHED |
| 220006427 | 220011413 | 1.63 | 0 | Curative (C) | 2014-06-08 | 2014-06-11 | null | N | null | 220030284 | NOT MATCHED |
| 220006428 | 220011413 | 1.62 | 76.7 | Curative (C) | 2016-02-01 | 2016-02-08 | AML 19 TRIAL | null | N | 220030284 | AML19 TRIAL |
| 220006429 | 220021732 | 1.7 | 53.8 | Curative (C) | 2014-07-02 | 2014-07-04 | AML 19 TRIAL | 02 | N | 220030294 | AML19 TRIAL |
| 220006430 | 220022004 | null | 0 | Disease modification (D) | 2017-12-22 | 2017-12-23 | Nilotinib | N | N | 220030295 | NILOTINIB |
| 220006431 | 220002479 | null | 70 | Curative (C) | 2014-08-20 | 2014-08-20 | AML Relapsed High Dose Cytarabine | null | null | 220030297 | NOT MATCHED |
| 220006432 | 220002479 | 0 | 82.7 | Palliative (P) | 2016-05-11 | 2016-05-11 | Nilotinib | 02 | N | 220030297 | NILOTINIB |
| 220006433 | 220002480 | 1.64 | 72.8 | Curative (C) | 2016-09-02 | 2016-09-03 | AML 19 TRIAL | 1 | N | 220030299 | AML19 TRIAL |
| 220006434 | 220002481 | 0 | 0 | Curative (C) | 2014-04-30 | 2014-04-30 | AML Downs AIE | N | N | 220030302 | NOT MATCHED |
| 220006435 | 220002481 | 1.69 | 68.8 | Curative (C) | null | 2015-01-15 | AML 19 TRIAL | 1 | N | 220030302 | AML19 TRIAL |
| 220006436 | 220002481 | 1.59 | 115.9 | Curative (C) | 2016-11-04 | 2016-11-04 | AML 19 TRIAL | Y | N | 220030302 | AML19 TRIAL |
| 220006437 | 220002481 | 1.85 | 104.2 | Curative (C) | 2016-06-30 | 2016-07-02 | AML 19 TRIAL | Y | N | 220030302 | AML19 TRIAL |
| 220006438 | 220002482 | 1.52 | 75.3 | Curative (C) | 2016-11-10 | 2016-11-13 | AML 19 TRIAL | Y | N | 220030310 | AML19 TRIAL |
| 220006439 | 220002482 | null | 81 | Curative (C) | 2016-09-23 | 2016-09-29 | AML 19 TRIAL | N | N | 220030310 | AML19 TRIAL |
| 220006442 | 220002484 | 1.78 | 79.2 | Curative (C) | 2014-06-02 | 2014-06-02 | AML 19 TRIAL | Y | N | 220030315 | AML19 TRIAL |
| 220006443 | 220002484 | 1.68 | 78.5 | Curative (C) | 2014-11-15 | 2014-11-15 | AML 19 TRIAL | Y | N | 220030315 | AML19 TRIAL |
| 220006444 | 220002485 | 0 | 0 | Disease modification (D) | 2016-03-13 | 2017-04-05 | Nilotinib | 2 | N | 220030318 | NILOTINIB |
| 220006445 | 220002485 | 1.66 | 97.2 | Curative (C) | 2014-12-19 | 2014-12-21 | AML 19 TRIAL | 1 | N | 220030318 | AML19 TRIAL |
| 220006446 | 220016143 | null | 108 | Curative (C) | 2017-03-24 | 2017-03-25 | AML 19 TRIAL | Y | N | 220030320 | AML19 TRIAL |
| 220006447 | 220016143 | 0 | null | Curative (C) | 2017-05-31 | 2017-05-31 | Nilotinib | 2 | N | 220030320 | NILOTINIB |
| 220006448 | 220016143 | 1.65 | 91.4 | Curative (C) | 2013-12-12 | 2013-12-12 | AML 19 TRIAL | N | N | 220030320 | AML19 TRIAL |